Singapore's latest HSA updates introduce several important changes for medical device manufacturers and registrants. The key highlights include:

  • Updated Product Registration Guidance: Revised ISO 13485 certification body requirements and updated guidance for ASEAN CSDT and IMDRF ToC-based submissions through SHARE.
  • New Premarket Submission Checklist: Applicable to Class B, C and D applications under specified evaluation routes from 1 October 2026, with stricter completeness requirements enforced from 1 January 2027.
  • Concurrent Change Notifications (CN): Up to two CN applications may be active simultaneously for the same device listing, provided that only one involves changes affecting device form fields.

Updated Medical Device Product Registration Guidance

On 30 September 2026, HSA published revised guidance documents, including GN-15-R15, GN-17-R5 and GN-18-R5, together with updated Product Registration Submission Guides.

The revisions clarify requirements for ISO 13485 certification bodies and incorporate International Medical Device Regulators Forum (IMDRF) Table of Contents (ToC)-based submission structures for general and in vitro diagnostic (IVD) medical devices, alongside the existing ASEAN Common Submission Dossier Template (CSDT) framework.

Under the latest GN-15-R15, certification bodies issuing ISO 13485 certificates must either be accredited by accreditation bodies recognised by Global Accreditation Cooperation Incorporated (Global ACI) or be EU MDR/IVDR Notified Bodies. Manufacturers should verify that their ISO 13485 certificates meet these requirements when preparing medical device registration submissions to HSA.

Introduction of the Premarket Submission Checklist

HSA introduced a Premarket Submission Checklist for Class B, C and D medical device registration applications submitted through the Full, Abridged and Expedited evaluation routes. Immediate Class B Registration (IBR), Immediate Class C Registration (ICR) and CN applications are excluded.

The checklist applies from 1 October 2026, with a grace period until 31 December 2026. From 1 January 2027, incomplete applications may be rejected without an input request for completeness deficiencies, and application fees will not be refunded.

The checklist consolidates existing submission requirements and helps applicants ensure that the necessary supporting documents are included before submission.

Clarifications on Concurrent Change Notifications

During its virtual sharing session on 24 September 2026, HSA clarified the concurrent CN mechanism, which has been permitted since 31 July 2026.

A maximum of two CN applications may be active concurrently for the same device listing, provided that only one involves changes affecting device form fields. A third CN application submitted while two applications remain active will be rejected in its entirety, with no refund of application fees.

HSA also clarified that dependencies between concurrent applications will be assessed on a case-by-case basis. The presentation slides and Frequently Asked Questions (FAQ), published on 30 September 2026, provide further practical guidance on both concurrent CN applications and the Premarket Submission Checklist.

Implications and Significance

These updates highlight the importance of maintaining accurate and complete regulatory documentation throughout the medical device lifecycle.

Companies preparing new product registration applications should review the revised HSA guidance, confirm the acceptability of their ISO 13485 certification documentation and incorporate the Premarket Submission Checklist into their internal submission procedures.

For registered medical devices, companies planning multiple changes should assess the number and nature of active CN applications and coordinate submissions accordingly.

In particular, manufacturers and registrants should prepare for the stricter submission completeness requirements taking effect on 1 January 2027 to minimise the risk of application rejection, additional costs and regulatory delays.

Contact our Singapore Team now!

Qualtech Consulting Corporation brings 26+ years of experience as a trusted partner to medical device manufacturers. We've successfully guided clients through countless dynamic regulatory and authority platform shifts across diverse international landscapes.

Whether you're a local startup or an international player, we empower your devices to enhance lives.

Contact us today here to unlock your medical device potential.

References

Teilen: